# NuvationConnect Enrollment Form

#### Please fax completed form to 1-877-NUV-CON4, or complete enrollment form online at NuvationConnect.com.

Please complete the required sections on the enrollment form for each type of support requested for the patient. These requirements apply only to support through NuvationConnect<sup>™</sup> and are not intended to limit any treatment, payment, or benefit activities with your pharmacy or other healthcare providers.

NuvationConnect Options (Check any of interest. All p	programs and support are subject to restrictions and eligibility requirements.)			
Authorization, Appeal Assistance       Complete sections         Complete sections       2       4       5       6       9       10       Copay Assistance	Ce Program (PAP)         Quick Start Program           s 2 4 5 6 8 9 10 11         Complete sections 2 4 5 6 8 9 10			
2 Patient Information				
Patient Name (first, last):	Home Phone:			
Date of Birth: / /	Cell Phone:			
Gender: Male Female Other	Email:			
Mailing Address:	PREFERRED CONTACT: Home Cell Email			
City/State: ZIP:	BEST TIME TO CONTACT:			
US Resident: Consent to leave voice messages at Consent to receive text messages:	the primary or alternative contact number: Yes No			
3 Alternate Contact/Caregiver Information (Opti	onal)			
Name (first, last):	PRIMARY CONTACT: Caregiver Patient			
Phone:	BEST TIME TO CONTACT:			
4 Insurance Information (If possible, include copies of b	both sides of the patient's insurance cards)			
PATIENT IS INSURED BY: (check all that apply)         Commercial/Private Insurance       Medicare Advantion         Medicare Part D (Prescription)       Medicaid         Other:       Other:	tage State Assistance Program for Medication			
PRIMARY INSURANCE	PRESCRIPTION INSURANCE			
Insurance:	Insurance:			
Insurance Phone:	Insurance Phone:			
Cardholder Name:	Cardholder Name:			
Member ID:	Member ID: Rx BIN#:			
Group #:	Rx PCN#: Rx GRP#:			

Fax form to 1-877-NUV-	CON4 or comp	lete online at N	uvationConnect.com
------------------------	--------------	------------------	--------------------



Prescriber Name (first, last):		Facility Name:	
Mailing Address:		Office Contact Name:	
City/State:	ZIP:	Office Contact Email:	
NPI#:		Office Phone:	
DEA#: Tax	ID#:	Office Fax:	
Clinical Information  Primary ICD-10 Code:		BIOMARKER STATUS/	TEST RESULTS: (check all that apply)
		ROS-1 Positive	G2032R-Positive
Secondary ICD-10 Code: PRIOR TREATMENT:		Most Recent Biomarke	
PRIOR TREATMENT:	therapy with IO/Immunotherapy TKI:	Most Recent Biomarke	
PRIOR TREATMENT:  Chemotherapy IO/Immunotherapy ROS-1	TKI:	Most Recent Biomarke	er Test Date: / / RIBTROZI™ (taletrectinib):
PRIOR TREATMENT:         Chemotherapy       Chemotherapy         IO/Immunotherapy       ROS-1         Specialty Pharmacy (Seletion)	TKI:	Most Recent Biomarke	er Test Date: / /  RIBTROZI™ (taletrectinib):  cond Line □ Third Line
PRIOR TREATMENT:         Chemotherapy       Chemotherapy         IO/Immunotherapy       ROS-1         Specialty Pharmacy       (Selettion)         Biologics by McKesson       O	TKI: ect one) nco360 🗌 No Preference [	Most Recent Biomarke	er Test Date: / /  RIBTROZI™ (taletrectinib):  cond Line □ Third Line
PRIOR TREATMENT:         Chemotherapy       Chemotherapy         IO/Immunotherapy       ROS-1         Specialty Pharmacy       Selection         Biologics by McKesson       O         Unless the patient requests differently or the inst cost sharing under the patient's insurance plan.	TKI: ect one) nco360 🗌 No Preference [	Most Recent Biomarke	er Test Date: / /  RIBTROZI™ (taletrectinib): cond Line □ Third Line
PRIOR TREATMENT:         Chemotherapy       Chemotherapy         IO/Immunotherapy       ROS-1         Specialty Pharmacy       Selection         Biologics by McKesson       O         Unless the patient requests differently or the inst cost sharing under the patient's insurance plan.	TKI: cct one) nco360 No Preference [ urance provider mandates the use of a specif	Most Recent Biomarke	er Test Date: / /  RIBTROZI™ (taletrectinib): cond Line □ Third Line
PRIOR TREATMENT:         Chemotherapy       Chemotherapy         IO/Immunotherapy       ROS-1         Specialty Pharmacy       Selection         Biologics by McKesson       O         Unless the patient requests differently or the insicost sharing under the patient's insurance plan.         Prescribing IBTROZI (Restription)	TKI: act one) nco360 No Preference [ urance provider mandates the use of a specif ictions and eligibility criteria apply	Most Recent Biomarke	er Test Date: / /  RIBTROZI <sup>TM</sup> (taletrectinib):  cond Line  Third Line  ite: be sent to the authorized pharmacy that offers the lowest
PRIOR TREATMENT:         Chemotherapy       Chemotherapy         IO/Immunotherapy       ROS-1         Specialty Pharmacy       ROS-1         Specialty Pharmacy       ROS-1         Biologics by McKesson       O         Unless the patient requests differently or the instruct plan.         Prescribing IBTROZI (Restr         PATIENT ASSISTANCE PROGRAM:         IBTROZI 200 mg capsules;         3 capsules once daily	TKI: TKI:	Most Recent Biomarke	er Test Date:       /         er Test Date:       /         RIBTROZI <sup>M</sup> (taletrectinib):         cond Line       Third Line         tite:       Third Line         be sent to the authorized pharmacy that offers the lowest         BRIDGE PROGRAM (current therapy)         IBTROZI 200 mg capsules;         3 capsules once daily
PRIOR TREATMENT:         Chemotherapy       Chemot         IO/Immunotherapy       ROS-1         Specialty Pharmacy       ROS-1         Specialty Pharmacy       Selection         Biologics by McKesson       O         Unless the patient requests differently or the inst cost sharing under the patient's insurance plan.         Prescribing IBTROZI (Restr         PATIENT ASSISTANCE PROGRAM:         IBTROZI 200 mg capsules; 3 capsules once daily (30-day supply).	TKI: act one) nco360 No Preference [ urance provider mandates the use of a specif ictions and eligibility criteria apply QUICK START PROGE IBTROZI 200 mg c 3 capsules once d (10-day supply).	Most Recent Biomarke	er Test Date:       /         RIBTROZITM (taletrectinib):         cond Line         Third Line         Site:         be sent to the authorized pharmacy that offers the lowest         BRIDGE PROGRAM (current therapy)         IBTROZI 200 mg capsules;         3 capsules once daily         (30-day supply).



/

Patient Name (first, last):

SIG

Date of Birth:

/

## Healthcare Professional Certification

By signing below, I hereby represent, covenant, and certify as follows:

(1) The above therapy (or medicine) is medically necessary for this patient and that I, as the prescriber, have made the decision to prescribe IBTROZI" (taletrectinib) (the "Product"); (2) I have obtained written consent from the patient (or from the patient's legal representative) as required by the Health Insurance Portability and Accountability Act (HIPAA) and other state and/or federal laws to release all of the patient's personal health information (PHI) needed for this form and such other PHI that Nuvation, NuvationConnect", the contracted dispensing pharmacy, or other contractors and may be required to (a) perform a preliminary verification of the patient's insurance coverage for the Product and (b) assess the patient's eligibility for participation in the NuvationConnect Program; (3) I understand that any Product provided at no charge to the patient is provided on a complimentary basis. I will not submit or cause to be submitted any claims for payment or reimbursement for such Product to any third-party payor, including, without limitation, a federal healthcare program. If I am or become in possession of such Product, I will not resell or attempt to resell the Product; (4) I have not received, nor will I seek or accept payment from my patient for any co-insurance amount paid for by the Product Copay Program for a Nuvation Bio product; (5) I understand that if my patient's insurance or financial status changes, the patient may no longer be eligible under this program. I will notify NuvationConnect if I become aware of any such changes; (6) I understand that I am under no obligation to prescribe any Nuvation Bio drug, and I have not received and will not receive any benefit from Nuvation Bio for prescribing a Nuvation Bio drug; (7) The information contained in this form is complete and accurate to the best of my knowledge; (8) I agree to comply with the NuvationConnect guidelines and understand that Nuvation Bio, at its sole and absolute discretion, reserves the right to modify or discontinue patient support programs, including such programs provided through NuvationConnect, at any time; and (9) I will notify NuvationConnect of any errors regarding the foregoing, and will make every effort to correct those errors.

Prescriber shall comply with applicable state prescribing requirements, such as e-prescribing, state-specific prescription form(s), fax language, etc. Noncompliance with applicable state prescribing requirements could result in additional communications from NuvationConnect or other contractors to the prescriber.

nat	ted Agent Name (please print):	Title:		
-	HCP Signature (no stamps, please):	Date:	/	/
	Designated Agent Signature (no stamps, please):	Date:	/	/



Patient Name (first, last):

Date of Birth:

/

### **10** Patient Authorization

I hereby authorize my healthcare professionals, my health insurance company, and my pharmacy to disclose my protected health information (PHI) including, but not limited to, my name, address, telephone number, medical records, health insurance coverage, and financial information with respect to my treatment, my eligibility for assistance, the coordination of my treatment, and receipt of my medication (collectively, my "Information") to NuvationConnect" and any third parties engaged to assist Nuvation in administering NuvationConnect for the purposes described below. I understand that once my information has been disclosed to NuvationConnect, it could be subject to redisclosure and that federal privacy laws may no longer protect the information. I authorize the release and use of my Information for the purposes of: (1) verifying, investigating, coordinating, and resolving insurance coverage or reimbursement, or payment inquiries, including by communicating with my healthcare providers and insurance company to verify my coverage and/or my medical care; (2) determining my eligibility for IBTROZI" (taletrectinib) (the "Product") and support through NuvationConnect; (3) enrolling me in and providing support through NuvationConnect, including facilitating the provision of the Product to me; (4) providing me with information regarding any independent patient assistance programs, patient advocacy organizations, or other alternate sources of funding, coverage, or support that may be available to provide assistance, including with out-of-pocket expenses; (5) coordinating my treatment with my healthcare professionals and specialty pharmacy; (6) providing me with information or materials related to NuvationConnect or the Product, including educational or promotional materials; (7) contacting me by phone, text, email or mail regarding this form or my use or potential use of the Product; (8) administering, evaluating, and improving NuvationConnect, the effectiveness of the Product, services, and programs, and helping to develop new products, services, and programs, and for other Nuvation general business and administrative purposes. I understand that if I refuse to sign this authorization, it will not affect my treatment by my healthcare professionals, or my payment, enrollment, or eligibility for benefits from my health plan. However, if I refuse to sign this authorization, or sign and then withdraw my authorization at a later date, it may affect my ability to participate in NuvationConnect. If I do not withdraw authorization, it will remain valid for 5 years (or at such lesser time as state law may require). I may withdraw this Authorization at any time by sending written notice to NuvationConnect at 13410 Eastpoint Centre Drive, Suite 150, Louisville, KY 40223. Withdrawal will stop further use or disclosure of my information, except as allowed by law or already relied upon. I am entitled to a copy of this signed Authorization, which expires 5 years after signing unless revoked earlier or otherwise specified by law.

By signing as the patient's representative or guardian, I confirm I am legally authorized to do so. Proof of this authority, such as a power of attorney or court order, may be requested.

Patient OR Legal Representative Name (please print):

SIGN HERE

Patient OR Legal Representative Signature:

#### **11** Patient Financial Consent (only required if applying for Patient Assistance Program)

Gross Annual Household Income:

No. of household members dependent on income (include applicant):

Date:

I understand that completing this form does not ensure my enrollment in the Patient Assistance Program ("PAP") and that certain eligibility criteria apply. By signing below, I certify that the information provided is complete and accurate. I authorize Nuvation Bio and any third parties engaged to administer the PAP to obtain documentation from me, my employer, or my insurance company to verify my financial or insurance information. I understand that Nuvation Bio may also make an independent determination of my financial need. I understand that if I am eligible to participate in the PAP, there is no purchase requirement associated with such assistance. I will not submit or cause to be submitted any claims for payment or reimbursement for any free supply of Product supplied under the PAP. Nuvation reserves the right at any time, and without notice, to modify or discontinue NuvationConnect and any assistance provided to me. I understand that I must re-apply for the PAP annually and there is no guarantee I will qualify at this time or in future periods. I understand that patients with insurance plans or employers participating in an alternate funding program (also sometimes referred to as patient advocacy programs, among other names) requiring them to apply to a manufacturer's patient to coverage of relevant Nuvation Bio products, or that otherwise denies, restricts, eliminates, delays, alters, or withholds any insurance benefits or coverage contingent upon application to, or denial of eligibility for, specialty drug prescription coverage through the alternate funding program are not eligible for the NuvationConnect PAP program. I understand that my health insurer(s) and pharmacy provider(s) may receive remuneration for the use or disclosure of my Information, as authorized above, and that once my Information has been disclosed to Nuvation Bio, my Information may no longer be protected by HIPAA or other federal and state privacy laws. I also understand, however, that Nuvation Bio plans to use and disclose my Inform

Patient OR Legal Representative Name (please print):

SIGN HERE Patient OR Legal Representative Signature:

Date:

/

